Free Trial

Evaxion A/S (EVAX) Competitors

Evaxion A/S logo
$6.79 -2.81 (-29.27%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$7.16 +0.38 (+5.52%)
As of 10/17/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EVAX vs. ELUT, PYRGF, VRCA, LIMN, NEUP, PLUR, MURA, MAAQ, ITRM, and TENX

Should you be buying Evaxion A/S stock or one of its competitors? The main competitors of Evaxion A/S include Elutia (ELUT), PyroGenesis Canada (PYRGF), Verrica Pharmaceuticals (VRCA), Liminatus Pharma (LIMN), Neuphoria Therapeutics (NEUP), Pluri (PLUR), Mural Oncology (MURA), Mana Capital Acquisition (MAAQ), Iterum Therapeutics (ITRM), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry.

Evaxion A/S vs. Its Competitors

Elutia (NASDAQ:ELUT) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

In the previous week, Evaxion A/S had 5 more articles in the media than Elutia. MarketBeat recorded 9 mentions for Evaxion A/S and 4 mentions for Elutia. Elutia's average media sentiment score of 0.32 beat Evaxion A/S's score of -0.11 indicating that Elutia is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Elutia
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Evaxion A/S
0 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Evaxion A/S has a net margin of 0.00% compared to Elutia's net margin of -90.01%. Elutia's return on equity of 0.00% beat Evaxion A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Elutia-90.01% N/A -54.08%
Evaxion A/S N/A -319.52%-63.56%

Elutia presently has a consensus target price of $7.00, indicating a potential upside of 685.90%. Evaxion A/S has a consensus target price of $11.00, indicating a potential upside of 62.00%. Given Elutia's higher possible upside, equities research analysts clearly believe Elutia is more favorable than Evaxion A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elutia
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Evaxion A/S
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

74.0% of Elutia shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 27.6% of Elutia shares are held by company insiders. Comparatively, 41.6% of Evaxion A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Evaxion A/S has lower revenue, but higher earnings than Elutia. Evaxion A/S is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elutia$23.68M1.59-$53.95M-$1.06-0.84
Evaxion A/S$3.34M2.85-$10.57M-$1.32-5.14

Elutia has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.

Summary

Elutia beats Evaxion A/S on 9 of the 14 factors compared between the two stocks.

Get Evaxion A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVAX vs. The Competition

MetricEvaxion A/SMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$9.52M$2.25B$6.19B$10.55B
Dividend YieldN/AN/A5.70%4.81%
P/E Ratio-5.1439.7185.5427.13
Price / Sales2.8517.69610.73132.72
Price / CashN/A59.9337.1060.81
Price / Book-5.7512.2912.236.52
Net Income-$10.57M-$65.79M$3.33B$276.93M
7 Day Performance15.08%0.97%1.17%1.93%
1 Month Performance119.74%4.06%6.85%2.19%
1 Year Performance-48.56%30.24%58.93%34.62%

Evaxion A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVAX
Evaxion A/S
1.9017 of 5 stars
$6.79
-29.3%
$11.00
+62.0%
-50.6%$9.52M$3.34M-5.1460Analyst Forecast
Short Interest ↑
Gap Down
ELUT
Elutia
3.1261 of 5 stars
$0.89
-1.3%
$7.00
+683.9%
-74.7%$37.86M$24.38M-0.84180
PYRGF
PyroGenesis Canada
0.5269 of 5 stars
$0.20
+5.3%
N/A-67.0%$37.59M$9.14M-3.3390News Coverage
VRCA
Verrica Pharmaceuticals
3.6952 of 5 stars
$3.97
-3.2%
$60.00
+1,411.3%
-74.1%$37.52M$7.57M-0.4840Short Interest ↑
LIMN
Liminatus Pharma
N/A$1.38
-2.1%
N/AN/A$37.36MN/A0.00N/ANegative News
Short Interest ↑
NEUP
Neuphoria Therapeutics
2.1251 of 5 stars
$15.71
-6.0%
$28.00
+78.2%
N/A$37.08M$15.65M0.00N/AGap Down
PLUR
Pluri
2.4297 of 5 stars
$4.50
+0.3%
$12.00
+167.0%
-10.6%$36.68M$1.34M-0.87150News Coverage
Positive News
MURA
Mural Oncology
3.3071 of 5 stars
$2.09
-0.2%
$12.00
+475.5%
-43.3%$36.13MN/A-0.24119
MAAQ
Mana Capital Acquisition
N/A$4.44
+6.9%
N/A+1,927.9%$36.03MN/A0.001
ITRM
Iterum Therapeutics
1.9754 of 5 stars
$0.74
+1.2%
$9.00
+1,117.9%
-42.4%$34.86MN/A-0.8710News Coverage
TENX
Tenax Therapeutics
1.857 of 5 stars
$7.50
+1.1%
$18.00
+140.2%
+69.1%$34.18MN/A-8.159News Coverage
Analyst Forecast
Short Interest ↑

Related Companies and Tools


This page (NASDAQ:EVAX) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners